Most Recent
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
Canadian generic manufacturer Apotex has agreed to drop its lawsuit against India's Cipla seeking to invalidate its Australian patent for popular nasal spray Dymista.
Law firm Slater and Gordon is investigating a class action against hospitals for encouraging "excessive and unsafe" work hours by doctors, some of whom the firm found routinely work up to 100 hours per week.
A judge overseeing a class action against the NSW government over a contractor who sold injured workers' information to Bannister Law has questioned the effectiveness of placing ads for group members on law firm websites, saying she didn't think it would "draw the matter to anyone's attention".
Mylan has appealed a ruling invaliding claims of its cholesterol drug patent and dismissing its patent infringement case against Sun Pharma.
Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator's landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.
AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser's Nuromol.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.